Population pharmacokinetics of antibacterial agents in the older population: a literature review.

IF 3.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Review of Clinical Pharmacology Pub Date : 2024-01-01 Epub Date: 2024-01-23 DOI:10.1080/17512433.2023.2295009

Hui-Xin Liu, Bo-Hao Tang, John van den Anker, Guo-Xiang Hao, Wei Zhao, Yi Zheng

{"title":"Population pharmacokinetics of antibacterial agents in the older population: a literature review.","authors":"Hui-Xin Liu, Bo-Hao Tang, John van den Anker, Guo-Xiang Hao, Wei Zhao, Yi Zheng","doi":"10.1080/17512433.2023.2295009","DOIUrl":null,"url":null,"abstract":"Introduction: Older individuals face an elevated risk of developing bacterial infections. The optimal use of antibacterial agents in this population is challenging because of age-related physiological alterations, changes in pharmacokinetics (PK) and pharmacodynamics (PD), and the presence of multiple underlying diseases. Therefore, population pharmacokinetics (PPK) studies are of great importance for optimizing individual treatments and prompt identification of potential risk factors.Area covered: Our search involved keywords such as 'elderly,' 'old people,' and 'geriatric,' combined with 'population pharmacokinetics' and 'antibacterial agents.' This comprehensive search yielded 11 categories encompassing 28 antibacterial drugs, including vancomycin, ceftriaxone, meropenem, and linezolid. Out of 127 studies identified, 26 (20.5%) were associated with vancomycin, 14 (11%) with meropenem, and 14 (11%) with piperacillin. Other antibacterial agents were administered less frequently.Expert opinion: PPK studies are invaluable for elucidating the characteristics and relevant factors affecting the PK of antibacterial agents in the older population. Further research is warranted to develop and validate PPK models for antibacterial agents in this vulnerable population.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"19-31"},"PeriodicalIF":3.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17512433.2023.2295009","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Older individuals face an elevated risk of developing bacterial infections. The optimal use of antibacterial agents in this population is challenging because of age-related physiological alterations, changes in pharmacokinetics (PK) and pharmacodynamics (PD), and the presence of multiple underlying diseases. Therefore, population pharmacokinetics (PPK) studies are of great importance for optimizing individual treatments and prompt identification of potential risk factors.

Area covered: Our search involved keywords such as 'elderly,' 'old people,' and 'geriatric,' combined with 'population pharmacokinetics' and 'antibacterial agents.' This comprehensive search yielded 11 categories encompassing 28 antibacterial drugs, including vancomycin, ceftriaxone, meropenem, and linezolid. Out of 127 studies identified, 26 (20.5%) were associated with vancomycin, 14 (11%) with meropenem, and 14 (11%) with piperacillin. Other antibacterial agents were administered less frequently.

Expert opinion: PPK studies are invaluable for elucidating the characteristics and relevant factors affecting the PK of antibacterial agents in the older population. Further research is warranted to develop and validate PPK models for antibacterial agents in this vulnerable population.

查看原文本刊更多论文

老年人口中抗菌药物的群体药代动力学：文献综述。

引言老年人患细菌感染的风险较高。由于与年龄相关的生理变化、药代动力学（PK）和药效学（PD）的变化以及多种潜在疾病的存在，在这一人群中优化使用抗菌药物具有挑战性。因此，群体药代动力学（PPK）研究对于优化个体治疗和及时发现潜在风险因素非常重要：我们的搜索涉及 "老年人"、"老人 "和 "老年病 "等关键词，以及 "群体药代动力学 "和 "抗菌药"。这一全面的搜索产生了 11 个类别，涵盖 28 种抗菌药物，包括万古霉素、头孢曲松、美罗培南和利奈唑胺。在确定的 127 项研究中，26 项（20.5%）与万古霉素有关，14 项（11%）与美罗培南有关，14 项（11%）与哌拉西林有关。其他抗菌药的使用频率较低：PPK研究对于阐明老年人群中影响抗菌药物PK的特征和相关因素非常有价值。有必要开展进一步研究，为这一易感人群开发和验证抗菌药的PPK模型。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Clinical Pharmacology PHARMACOLOGY & PHARMACY-

CiteScore

7.30

自引率

2.30%

发文量

127

期刊介绍： Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery. Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.